Overview

Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.
Phase:
Phase 4
Details
Lead Sponsor:
Innovative Medical
Treatments:
Cyclosporine
Cyclosporins